New technologies in the therapeutic antibody development

Current Opinion in Pharmacology

Volumn 3, Issue 5, 2003, Pages 544-550

  Brekke, O H ^a,b   Loset G A ^a,b  

^a Affitech AS   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4B5; ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; AMG 714; ANTIBODY; BASILIXIMAB; BELIMUMAB; BERTILIMUMAB; CDP 860; CERTOLIZUMAB PEGOL; DACLIZUMAB; EDRECOLOMAB; GEMTUZUMAB OZOGAMICIN; H 11 SCFV; HERZEPTIN; HUMAX INFLAM; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN HEAVY CHAIN; INFLIXIMAB; IPILIMUMAB; J 695; LEDERLIMUMAB; LERDELIMUMAB; MDX 060; MDX 070; METELIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRAIL R 1; OKT 3; OMALIZUMAB; ORTHOCLONE OKT 3; PALIVIZUMAB; PANITUMUMAB; REPRO; RHUFAB; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANOLIMUMAB;

AUTOIMMUNE DISEASE; BIOTECHNOLOGY; CANCER; CLINICAL TRIAL; DRUG DESIGN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG PENETRATION; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; INFECTION; INFLAMMATION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES; DRUG DESIGN; HALF-LIFE; HUMANS; PROTEIN ENGINEERING; TECHNOLOGY, PHARMACEUTICAL;

EID: 0141758337     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.05.002     Document Type: Review

References (60)

1. Kohler G. Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495-497
2. Morrison S.L. Johnson M.J. Herzenberg L.A. Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc. Natl. Acad. Sci. U.S.A. 81 1984 6851-6855
3. Jones P.T. Dear P.H. Foote J. Neuberger M.S. Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 321 1986 522-525
4. Khazaeli M.B. Conry R.M. LoBuglio A.F. Human immune response to monoclonal antibodies J. Immunother. 15 1994 42-52
5. Bell S.J. Kamm M.A. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease Aliment Pharmacol. Ther. 14 2000 501-514
6. Moghaddam A. Lobersli I. Gebhardt K. Braunagel M. Marvik O.J. Selection and characterisation of recombinant single-chain antibodies to the hapten Aflatoxin-B1 from naive recombinant antibody libraries J. Immunol. Methods 254 2001 169-181
7. Zhou B. Wirsching P. Janda K.D. Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat Proc. Natl. Acad. Sci. U.S.A. 99 2002 5241-5246
8. Moghaddam A, Borgen T, Stacy J, Kausmally L, Simonsen B, Marvik OJ, Brekke OH, Braunagel M: Identification of scFv antibody fragments that specifically recognise the heroin metabolite 6-mono acetylmorphine but not morphine. J Immunol Methods 2003, in press.
9. McCafferty J. Griffiths A.D. Winter G. Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains Nature 348 1990 552-554
10. Vaughan T.J. Williams A.J. Pritchard K. Osbourn J.K. Pope A.R. Earnshaw J.C. McCafferty J. Hodits R.A. Wilton J. Johnson K.S. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library Nat. Biotechnol. 14 1996 309-314
11. Little M. Welschof M. Braunagel M. Hermes I. Christ C. Keller A. Rohrbach P. Kurschner T. Schmidt S. Kleist C. et al. Generation of a large complex antibody library from multiple donors J. Immunol. Methods 231 1999 3-9
12. de Haard H.J. van Neer N. Reurs A. Hufton S.E. Roovers R.C. Henderikx P. de Bruine A.P. Arends J.W. Hoogenboom H.R. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies J. Biol. Chem. 274 1999 18218-18230
13. Sblattero D. Bradbury A. Exploiting recombination in single bacteria to make large phage antibody libraries Nat. Biotechnol. 18 2000 75-80
14. Knappik A. Ge L. Honegger A. Pack P. Fischer M. Wellnhofer G. Hoess A. Wolle J. Pluckthun A. Virnekas B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides J. Mol. Biol. 296 2000 57-86
15. Soderlind E. Strandberg L. Jirholt P. Kobayashi N. Alexeiva V. Aberg A.M. Nilsson A. Jansson B. Ohlin M. Wingren C. et al .Recombining germline-derived CDR sequences for creating diverse single- framework antibody libraries Nat. Biotechnol. 18 2000 852-856
16. Burton D.R. Barbas C.F. III Persson M.A. Koenig S. Chanock R.M. Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals Proc. Natl. Acad. Sci. U.S.A. 88 1991 10134-10137
17. Graus Y.F. Verschuuren J.J. Degenhardt A. van Breda Vriesman P.J. De Baets M.H. Posner J.B. Burton D.R. Dalmau J. Selection of recombinant anti-HuD Fab fragments from a phage display antibody library of a lung cancer patient with paraneoplastic encephalomyelitis J. Neuroimmunol. 82 1998 200-209
18. Hansen M.H. Nielsen H. Ditzel H.J. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells Proc. Natl. Acad. Sci. U.S.A. 98 2001 12659-12664
19. Wu H. Pancook J.D. Beuerlein G. Chilton T. Pecht G. Huse W.D. Watkins J.D. Cloning, isolation and characterization of human tumor in situ monoclonal antibodies Cancer Immunol. Immunother. 51 2002 79-90
20. de Wildt R.M. Mundy C.R. Gorick B.D. Tomlinson I.M. Antibody arrays for high-throughput screening of antibody-antigen interactions Nat. Biotechnol. 18 2000 989-994
21. Walter G. Bussow K. Lueking A. Glokler J. High-throughput protein arrays: prospects for molecular diagnostics Trends Mol. Med. 8 2002 250-253
22. Hanes J. Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display Proc. Natl. Acad. Sci. U.S.A. 94 1997 4937-4942
23. He M. Taussig M.J. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites Nucleic Acids Res. 25 1997 5132-5134
24. Hanes J. Schaffitzel C. Knappik A. Pluckthun A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display Nat. Biotechnol. 18 2000 1287-1292
25. Irving R.A. Coia G. Roberts A. Nuttall S.D. Hudson P.J. Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics J. Immunol. Methods 248 2001 31-45
26. FitzGerald K. In vitro display technologies - new tools for drug discovery Drug Discov. Today 5 2000 253-258
27. Feldhaus M.J. Siegel R.W. Opresko L.K. Coleman J.R. Feldhaus J.M. Yeung Y.A. Cochran J.R. Heinzelman P. Colby D. Swers J. et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library Nat. Biotechnol. 21 2003 163-170
28. Kellermann S.A. Green L.L. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics Curr. Opin. Biotechnol. 13 2002 593-597
29. Green L.L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies J. Immunol. Methods 231 1999 11-23
30. He Y. Honnen W.J. Krachmarov C.P. Burkhart M. Kayman S.C. Corvalan J. Pinter A. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci J. Immunol. 169 2002 595-605
31. Ward E.S. Gussow D. Griffiths A.D. Jones P.T. Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli Nature 341 1989 544-546
32. Hamers-Casterman C. Atarhouch T. Muyldermans S. Robinson G. Hamers C. Songa E.B. Bendahman N. Hamers R. Naturally occurring antibodies devoid of light chains Nature 363 1993 446-448
33. Nuttall S.D. Krishnan U.V. Hattarki M. De Gori R. Irving R.A. Hudson P.J. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries Mol. Immunol. 38 2001 313-326
34. Dumoulin M. Conrath K. Van Meirhaeghe A. Meersman F. Heremans K. Frenken L.G. Muyldermans S. Wyns L. Matagne A. Single-domain antibody fragments with high conformational stability Protein Sci. 11 2002 500-515
35. Muyldermans S. Single domain camel antibodies: current status J. Biotechnol. 74 2001 277-302
36. Els Conrath K. Lauwereys M. Wyns L. Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs J. Biol. Chem. 276 2001 7346-7350
37. Ramjiawan B. Maiti P. Aftanas A. Kaplan H. Fast D. Mantsch H.H. Jackson M. Noninvasive localization of tumors by immunofluorescence imaging using a single chain Fv fragment of a human monoclonal antibody with broad cancer specificity Cancer 89 2000 1134-1144
38. Holliger P. Prospero T. Winter G. Diabodies: small bivalent and bispecific antibody fragments Proc. Natl. Acad. Sci. U.S.A. 90 1993 6444-6448
39. Iliades P. Kortt A.A. Hudson P.J. Triabodies: single chain Fv fragments without a linker form trivalent trimers FEBS Lett. 409 1997 437-441
40. Kortt A.A. Dolezal O. Power B.E. Hudson P.J. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting Biomol. Eng. 18 2001 95-108
41. Holliger P. Brissinck J. Williams R.L. Thielemans K. Winter G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody Protein Eng. 9 1996 299-305
42. Cochlovius B. Kipriyanov S.M. Stassar M.J. Christ O. Schuhmacher J. Strauss G. Moldenhauer G. Little M. Treatment of human B cell lymphoma xenografts with a CD3 X CD19 diabody and T cells J. Immunol. 165 2000 888-895
43. Begent R.H. Verhaar M.J. Chester K.A. Casey J.L. Green A.J. Napier M.P. Hope-Stone L.D. Cushen N. Keep P.A. Johnson C.J. et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library Nat. Med. 2 1996 979-984
44. Behr T.M. Goldenberg D.M. Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations Eur. J. Nucl. Med. 25 1998 201-212
45. Wu A.M. Yazaki P.J. Tsai S. Nguyen K. Anderson A.L. McCarthy D.W. Welch M.J. Shively J.E. Williams L.E. Raubitschek A.A. et al.High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment Proc. Natl. Acad. Sci. U.S.A. 97 2000 8495-8500
46. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review Adv. Drug. Deliv. Rev. 54 2002 531-545
47. Choy E.H. Hazleman B. Smith M. Moss K. Lisi L. Scott D.G. Patel J.Sopwith M.Isenberg D.A.Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial Rheumatology (Oxford) 41 2002 1133-1137
48. Xia M.Q. Hale G. Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen Mol. Immunol. 30 1993 1089-1096
49. Cragg M.S. French R.R. Glennie M.J. Signaling antibodies in cancer therapy Curr. Opin. Immunol. 11 1999 541-547
50. Michaelsen T.E. Garred P. Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration Eur. J. Immunol. 21 1991 11-16
51. Norderhaug L. Brekke O.H. Bremnes B. Sandin R. Aase A. Michaelsen T.E. Sandlie I. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge Eur. J. Immunol. 21 1991 2379-2384
52. Brekke O.H. Michaelsen T.E. Sandin R. Sandlie I. Activation of complement by an IgG molecule without a genetic hinge Nature 363 1993 628-630
53. Furebring C. Speckner A. Mach M. Sandlie I. Norderhaug L. Borrebaeck C.A. Turesson H.Ohlin M.Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region Mol. Immunol. 38 2002 833-840
54. Idusogie E.E. Wong P.Y. Presta L.G. Gazzano-Santoro H. Totpal K. Ultsch M. Mulkerrin M.G. Engineered antibodies with increased activity to recruit complement J. Immunol. 166 2001 2571-2575
55. Shields R.L. Lai J. Keck R. O'Connell L.Y. Hong K. Meng Y.G. Weikert S.H. Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity J. Biol. Chem. 277 2002 26733-26740
56. Salfeld J. Kaymakzalan Z. Tracey D. Roberts A. Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract] Arthritis Rheum 41 1998 57
57. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials Ann. Rheum Dis. 61Suppl. 2 2002 ii70-ii73
58. den Broeder A.A. Joosten L.A. Saxne T. Heinegard D. Fenner H. Miltenburg A.M. Frasa W.L.van Tits L.J.Buurman W.A.van Riel P.L. et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann. Rheum Dis. 61 2002 311-318
59. Maini R.N. Breedveld F.C. Kalden J.R. Smolen J.S. Davis D. Macfarlane J.D. Antoni C. Leeb B. Elliott M.J. Woody J.N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552-1563
60. New Medicines in Development for Biotechnology: 2002. [URL: http://www.phrma.org/newmedicines/biotech